|

CD123 targeted CAR-NK cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Chongqing Precision Biotech Co., Ltd1

Indications

  • Relapse Leukemia1
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)1
  • Refractory Leukemia1
  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.